A client who is taking dextroamphetamine-amphetamine extended-release tablets for attention deficit hyperactivity disorder (ADHD), reports about having difficulty sleeping at night. Which assessment is most important for the nurse to obtain?

A) Serum ammonia level of 30 pg/dl (17.62 μmol /dL): Serum ammonia level is not directly affected by sodium polystyrene sulfonate administration. Ammonia levels are typically related to liver function and are not relevant in assessing the effectiveness of this medication for hyperkalemia.
B) Serum glucose level of 120 mg/dL (6.7 mmol/L): Serum glucose level is unrelated to the action of sodium polystyrene sulfonate. While hyperkalemia can sometimes lead to glucose metabolism abnormalities, the glucose level alone does not provide information about the medication's effectiveness.
C) Serum potassium level of 3.8 mEq/L (3.8 mmol/L): Sodium polystyrene sulfonate, also known as Kayexalate, is a medication used to treat hyperkalemia by exchanging sodium ions for potassium ions in the intestines, leading to potassium excretion through feces. A decrease in serum potassium level within the normal range indicates that the medication has been effective in lowering potassium levels, which is the intended therapeutic outcome in the context of treating hyperkalemia associated with acute kidney injury (AKI).
D) Hemoglobin level of 13.5 g/dL (135 g/L): Hemoglobin level is unrelated to the action of sodium polystyrene sulfonate. It reflects the oxygen-carrying capacity of red blood cells and is not directly influenced by potassium-lowering medications.

A) Monitor blood pressure:
This is the correct answer. Tamsulosin, like other alpha-blockers, can cause orthostatic hypotension, which is characterized by a sudden drop in blood pressure when transitioning from lying down or sitting to standing. Monitoring blood pressure, particularly when initiating therapy or adjusting the dosage, helps detect and manage hypotensive episodes. Clients should be advised to change positions slowly to minimize the risk of falls or injury.

B) Assess urine output:
While tamsulosin can affect urinary function by relaxing smooth muscle in the prostate and bladder neck, it typically does not significantly impact urine output. Therefore, monitoring urine output is not a primary intervention for assessing adverse reactions to tamsulosin.

C) Obtain daily weights:
Tamsulosin is not typically associated with significant fluid retention or changes in body weight. Daily weight measurements are more relevant for assessing fluid balance in clients receiving medications such as diuretics or those with conditions like heart failure or renal disease.

D) Perform a bladder scan:
Tamsulosin does not directly affect bladder volume or urinary retention to the extent that necessitates routine bladder scanning. Bladder scans are typically performed in clients with suspected urinary retention or those at risk for urinary retention due to conditions like BPH, but it's not a standard intervention for monitoring adverse reactions to tamsulosin.